Abstracts tagged "Biologics and psoriatic arthritis"

Abstract Number: 807 • 2019 ACR/ARP Annual Meeting
Guselkumab, an Anti-interleukin-23p19 Monoclonal Antibody, in Patients with Active Psoriatic Arthritis Who Were Biologic-Naïve or Prior TNFα Inhibitor-Treated: Week 24 Results of a Phase 3, Randomized, Double-blind, Placebo-controlled Study
Atul Deodhar¹, Philip Helliwell ², Wolf-Henning Boencke ³, Elizabeth Hsia ⁴, Alexa Kollmeier ⁵, Ramanand Subramanian ⁵, Xie Xu ⁵, Shihong Sheng ⁵, Bei Zhou ⁵ and Christopher Ritchlin ⁶, ¹Oregon Health & Science University, Portland, OR, ²University of Leeds, Leeds, United Kingdom, ³Geneva Univ Hospitals, Geneva, Switzerland, ⁴Janssen Research & Development, LLC/University of Pennsylvania, Spring House/Philadelphia, PA, ⁵Janssen Research & Development, LLC, Spring House, PA, ⁶Division of Allergy, Immunology and Rheumatology, Center for Musculoskeletal Research, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA, Rochester, NY
Background/Purpose: Guselkumab (GUS), an anti-interleukin-23p19 monoclonal antibody, is approved to treat PsO. We evaluated GUS efficacy and safety in a Phase 3, double-blind, PBO-controlled trial…
Abstract Number: 2846 • 2015 ACR/ARHP Annual Meeting
Modifications to Biologic Therapy and Economic Implications in Psoriatic Arthritis Patients
Jacqueline B. Palmer, Yunfeng Li, Vivian Herrera, Minlei Liao and Zafer Ozturk, Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Limited information exists on the long term real-world treatment patterns of biologics for psoriatic arthritis (PsA) in the US population. We assessed medication persistence…
Abstract Number: 539 • 2014 ACR/ARHP Annual Meeting
Efficacy and Safety of Ustekinumab in Psoriatic Arthritis Patients with Spondylitis and Peripheral Joint Involvement: Results from a Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study
Arthur Kavanaugh¹, Lluís Puig Sanz², Alice B. Gottlieb³, Christopher T. Ritchlin⁴, Yin You⁵, Yuhua Wang⁵, Alan M. Mendelsohn⁶, Michael Song⁵, Proton Rahman⁷ and Iain B. McInnes⁸, ¹University of California San Diego, La Jolla, CA, ²Dermatology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ³Tufts Medical Center, Boston, MA, ⁴Allergy Immunology & Rheumatology, University of Rochester Medical Center, Rochester, NY, ⁵Janssen Research & Development, LLC., Spring House, PA, ⁶Immunology, Janssen Research & Development, LLC., Spring House, PA, ⁷Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ⁸University of Glasgow, Glasgow, United Kingdom
Background/Purpose: IL-23 may be implicated in spondylitis. A substantial number of pts with spondylitis and peripheral joint involvement were enrolled in PSUMMIT. We evaluated the…
Abstract Number: 302 • 2013 ACR/ARHP Annual Meeting
Maintenance Of Efficacy and Safety Of Ustekinumab In Patients With Active Psoriatic Arthritis Despite Prior Conventional Nonbiologic and Anti-TNF Biologic Therapy: 1‑year Results Of a Phase 3, Multicenter, Double-Blind, Placebo-Controlled Trial
Christopher T. Ritchlin¹, Iain B. McInnes², Arthur Kavanaugh³, Lluis Puig⁴, Proton Rahman⁵, Carrie Brodmerkel⁶, Shu Li⁶, Yaung-Kaung Shen⁶, Mittie K. Doyle⁶, Alan M. Mendelsohn⁷ and Alice B. Gottlieb⁸, ¹Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ²Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, ³University of California, San Diego, La Jolla, CA, ⁴Universitat Autònoma de Barcelona, Barcelona, Spain, ⁵Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ⁶Janssen Research & Development, LLC., Spring House, PA, ⁷Immunology, Janssen Research & Development, LLC., Spring House, PA, ⁸Tufts Medical Center, Boston, MA
Background/Purpose: Ustekinumab (UST) has demonstrated substantial efficacy and an acceptable safety profile, and is approved for use, in treating moderate-to-severe psoriasis. UST has also demonstrated…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].